Seres therapeutics reports second quarter 2023 financial results and provides business updates

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported second quarter 2023 financial results and provided business updates. “seres achieved a major corporate milestone during the second quarter with the fda approval of vowst, the first and only fda-approved orally administered microbiome therapeutic for the treatment of adult recurrent c. difficile infection patients, including those with first recurrence,” said eric.
MCRB Ratings Summary
MCRB Quant Ranking